Home - 789-Platinum

platinum 789Final analysis of the phase III KEYNOTE-789 trial evaluating pemetrexedplatinum chemotherapy with or without pembrolizumab in TKI-resistant, EGFR-mutated, metastaticKeynote-789. KEYNOTE-789 was a randomized, double-blind phase 3 study. 18 It was desned to evaluate the addition of pembrolizumab to platinum-based chemotherapy in